Compare ALSN & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALSN | ROIV |
|---|---|---|
| Founded | 1915 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 14.1B |
| IPO Year | 2012 | N/A |
| Metric | ALSN | ROIV |
|---|---|---|
| Price | $98.91 | $23.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $94.43 | $21.94 |
| AVG Volume (30 Days) | 1.1M | ★ 6.7M |
| Earning Date | 10-29-2025 | 11-10-2025 |
| Dividend Yield | ★ 1.08% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 8.15 | N/A |
| Revenue | ★ $3,069,000,000.00 | $20,329,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.10 | $376.94 |
| P/E Ratio | $12.25 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $76.01 | $8.73 |
| 52 Week High | $121.81 | $22.45 |
| Indicator | ALSN | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 75.32 | 71.09 |
| Support Level | $93.07 | $20.14 |
| Resistance Level | $101.55 | $21.48 |
| Average True Range (ATR) | 2.40 | 0.77 |
| MACD | 0.93 | 0.09 |
| Stochastic Oscillator | 81.02 | 88.97 |
Allison Transmission is the largest manufacturer of fully automatic transmissions for medium- and heavy-duty commercial vehicles. Its automatic transmissions allow customers to achieve better fuel and operator efficiency than less expensive manual and automated manual transmissions. Allison serves several end markets, including on- and off-highway equipment and military vehicles. Its on-highway business commands approximately 60% global market share. The company's transmissions can be found in Class 4-8 trucks, buses, and a limited number of large passenger vehicles (heavy-duty pickup trucks and motorhomes). Allison also produces commercial hybrid propulsion systems and is developing fully electric powertrains.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.